Anthramycin
Modify Date: 2024-01-06 18:14:29
Anthramycin structure
|
Common Name | Anthramycin | ||
|---|---|---|---|---|
| CAS Number | 4803-27-4 | Molecular Weight | 315.32400 | |
| Density | 1.505 g/cm3 | Boiling Point | 679.872ºC at 760mmHg | |
| Molecular Formula | C16H17N3O4 | Melting Point | 188-194ºC | |
| MSDS | N/A | Flash Point | 364.974ºC | |
Use of AnthramycinAnthramycin, a member of the pyrolobenzodiazepine (PBD) family, is a potent antibiotic. Anthramycin has potent antitumor activity. Anthramycin can act as an potent antagonist of cholecystokinin in the central nervous system in mice[1][2][3]. |
| Name | Anthramycin |
|---|---|
| Synonym | More Synonyms |
| Description | Anthramycin, a member of the pyrolobenzodiazepine (PBD) family, is a potent antibiotic. Anthramycin has potent antitumor activity. Anthramycin can act as an potent antagonist of cholecystokinin in the central nervous system in mice[1][2][3]. |
|---|---|
| Related Catalog | |
| In Vitro | ANT is delivered through the skin for PG (propylene glycol), TC (Transcutol P) and PGML (propylene glycol monolaurate) with the active “tracking” the skin penetration of both PG and TC[1]. Anthramycin (10-1000 μM) dose not affect the ATPase activity of heart mitochondria[3]. |
| In Vivo | Anthramycin (0-0.5 mg/kg, IP, once) has potent anti-CCK (cholecystokinin) activity and antinociceptive effects in the central nervous system in mice[2]. Anthramycin (0.1-0.5 mg/kg, SC, daily for 8 days) has no effect on mitochondrial metabolism of the rat heart[3]. Animal Model: Male ddY mice (20 ± 2 g, 12-14 each group)[2] Dosage: 0, 0.3, and 0.5 mg/kg Administration: IP, once, 10 min before the intracisternal (i.c.) injection of CCK Result: Significantly inhibited CCK-induced increase in the pain threshold in a dose-dependent manner. Almost completely suppressed the antinociceptive effects of CCK at the higher dose (0.5 mg/kg). Animal Model: Female CFN Gif rats (140-180 g)[3] Dosage: 0.1 mg/kg, 0.25 mg/kg, and 0.5 mg/kg Administration: SC, daily for 8 days Result: Recorded no differences between anthramycin- and DMSO-treated rats with respect to P/O ratios, respiration rates, and ATPase activity of heart mitochondria. |
| References |
| Density | 1.505 g/cm3 |
|---|---|
| Boiling Point | 679.872ºC at 760mmHg |
| Melting Point | 188-194ºC |
| Molecular Formula | C16H17N3O4 |
| Molecular Weight | 315.32400 |
| Flash Point | 364.974ºC |
| Exact Mass | 315.12200 |
| PSA | 115.89000 |
| LogP | 1.36060 |
| Index of Refraction | 1.723 |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
MUTATION DATA
|
| (11R,11aS)-5,10,11,11a-tetrahydro-9,11-dihydroxy-8-methyl-5-oxo-1H-pyrrolo<2,1-c><1,4>benzodiazepin-2-trans-acrylamid |
| 3-(9,11-dihydroxy-8-methyl-5-oxo-5,10,11,11a-tetrahydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepine-2-yl)-acrylamide |
| Antramycin |